Skip to content

Study · Non-randomized trial · n = 150 · 2025

4 results

Cerebrolysin as an adjuvant therapy after mechanical thrombectomy in large vessel occlusion cardioembolic stroke: a propensity score matching analysis.

ElBassiouny A, Shehata MSA, Zaki AS, Bedros RY, El-Sudany AH, Nasser AA

Frontiers in neurology13 Feb 2025Cited by 9 (Europe PMC)

PMID40027163 (opens in a new tab)PMCIDPMC11868704 (opens in a new tab)DOI10.3389/fneur.2025.1510284 (opens in a new tab)PepBankPUB-40027163
Download PDFPubMedAsk about this study
Jump to 4 results

Summary

IntroductionEndovascular recanalization therapy has demonstrated considerable efficacy in the treatment of acute ischemic stroke (AIS). However, not all patients appear to benefit on the long term from this therapy. No studies have assessed the role of Cerebrolysin following mechanical thrombectomy (MT). The present study was conducted to evaluate the safety and efficacy of Cerebrolysin as add-on treatment to MT in patients with cardioembolic AIS.MethodsThis study evaluated 150 patients admitted to the stroke unit. Data were prospectively collected from 75 patients with cardioembolic AIS and National Institutes of Health Stroke Scale (NIHSS) ≥10, who underwent successful MT ± recombinant tissue plasminogen activator (rt-PA). Patients fulfilling inclusion criteria were consecutively enrolled and treated with Cerebrolysin at a daily dose of 30 ml for 14 days, with treatment initiated within 8 h following MT. Patients were compared with a historical control group of 75 well-matched patients who underwent MT ± rt-PA but did not receive Cerebrolysin. The primary outcome measure was a favorable modified Rankin Scale (mRS = 0-2) at day 90. Secondary parameters included the NIHSS, the Montreal Cognitive Assessment (MoCA), the rate of hemorrhagic transformation, mortality, and adverse events. Propensity score matching was performed to match the variables between the compared groups.Results and discussionThe overall results demonstrated that patients treated with Cerebrolysin exhibited a significantly higher proportion of mRS scores of 0-2 at day 90 (64% vs. 34.7%) in comparison to the control group. This finding was consistent with lower NIHSS and mRS scores at all study visits, and a lower any hemorrhagic transformation rate (20% vs. 57.3%). Furthermore, the logistic regression analysis revealed that patients with favorable mRS scores were less likely to undergo hemorrhagic transformation (odds ratio = 2.75, 95% confidence interval = 1.17, 6.45; p = 0.002). The administration of Cerebrolysin as an add-on treatment resulted in a significant benefit for AIS patients following MT, characterized by an improvement in mRS and NIHSS scores, along with a reduced rate of hemorrhagic transformation. The administration of Cerebrolysin was safe and well tolerated. Further studies are required to confirm these results.
CC BYText from Europe PMC. Highlighted sentences are the source of results.

Results from this study4

4 results from studies that gave the peptide. 4 results from people.

  1. 01HumanNon-randomized trialEfficacy outcome

    In cardioembolic stroke patients after thrombectomy, Cerebrolysin increased favorable mRS outcomes versus historical controls.

    In plain wordsIn stroke patients after thrombectomy, Cerebrolysin increased favorable disability outcomes versus historical controls.

    Peptide
    Cerebrolysin
    Outcome
    IncreaseFavorable mRS at day 90
    Study

    n = 150

    Comparator
    Historical controls receiving mechanical thrombectomy without Cerebrolysin
    Analysis
    Primary
    Outcome group
    Neuroprotection · Nervous system and cognition
    Studied dose
    30 ml daily · 14 daysAs given in this study (human).

    Measurements

    Favorable mRS
    64%
    Cerebrolysin
    Favorable mRS
    34.7%
    control

    Source sentences

    Summary
    The overall results demonstrated that patients treated with Cerebrolysin exhibited a significantly higher proportion of mRS scores of 0-2 at day 90 (64% vs. 34.7%) in comparison to the control group.
    3 context sentences
    Summary · context
    Data were prospectively collected from 75 patients with cardioembolic AIS and National Institutes of Health Stroke Scale (NIHSS) ≥10, who underwent successful MT ± recombinant tissue plasminogen activator (rt-PA).
    Summary · context
    Patients fulfilling inclusion criteria were consecutively enrolled and treated with Cerebrolysin at a daily dose of 30 ml for 14 days, with treatment initiated within 8 h following MT.
    Summary · context
    Patients were compared with a historical control group of 75 well-matched patients who underwent MT ± rt-PA but did not receive Cerebrolysin.
  2. 02HumanNon-randomized trialEfficacy outcome

    In cardioembolic stroke patients after thrombectomy, Cerebrolysin reduced NIHSS scores at all visits versus historical controls.

    In plain wordsIn stroke patients after thrombectomy, Cerebrolysin reduced neurological deficit scores at all visits versus historical controls.

    Peptide
    Cerebrolysin
    Outcome
    DecreaseNIHSS scores
    Study

    n = 150

    Comparator
    Historical controls receiving mechanical thrombectomy without Cerebrolysin
    Analysis
    Secondary
    Outcome group
    Neuroprotection · Nervous system and cognition
    Studied dose
    30 ml daily · 14 daysAs given in this study (human).

    Source sentences

    Summary
    This finding was consistent with lower NIHSS and mRS scores at all study visits, and a lower any hemorrhagic transformation rate (20% vs. 57.3%).
    3 context sentences
    Summary · context
    Data were prospectively collected from 75 patients with cardioembolic AIS and National Institutes of Health Stroke Scale (NIHSS) ≥10, who underwent successful MT ± recombinant tissue plasminogen activator (rt-PA).
    Summary · context
    Patients fulfilling inclusion criteria were consecutively enrolled and treated with Cerebrolysin at a daily dose of 30 ml for 14 days, with treatment initiated within 8 h following MT.
    Summary · context
    Patients were compared with a historical control group of 75 well-matched patients who underwent MT ± rt-PA but did not receive Cerebrolysin.
  3. 03HumanNon-randomized trialSafety outcome

    In cardioembolic stroke patients after thrombectomy, Cerebrolysin reduced hemorrhagic transformation versus historical controls.

    In plain wordsIn stroke patients after thrombectomy, Cerebrolysin reduced hemorrhagic transformation versus historical controls.

    Peptide
    Cerebrolysin
    Outcome
    DecreaseAny hemorrhagic transformation
    Study

    n = 150

    Comparator
    Historical controls receiving mechanical thrombectomy without Cerebrolysin
    Analysis
    Secondary
    Outcome group
    Adverse events · Nervous system and cognition
    Studied dose
    30 ml daily · 14 daysAs given in this study (human).

    Measurements

    Hemorrhagic transformation
    20%
    Cerebrolysin
    Hemorrhagic transformation
    57.3%
    control

    Source sentences

    Summary
    This finding was consistent with lower NIHSS and mRS scores at all study visits, and a lower any hemorrhagic transformation rate (20% vs. 57.3%).
    3 context sentences
    Summary · context
    Data were prospectively collected from 75 patients with cardioembolic AIS and National Institutes of Health Stroke Scale (NIHSS) ≥10, who underwent successful MT ± recombinant tissue plasminogen activator (rt-PA).
    Summary · context
    Patients fulfilling inclusion criteria were consecutively enrolled and treated with Cerebrolysin at a daily dose of 30 ml for 14 days, with treatment initiated within 8 h following MT.
    Summary · context
    Patients were compared with a historical control group of 75 well-matched patients who underwent MT ± rt-PA but did not receive Cerebrolysin.
  4. 04HumanNon-randomized trialEfficacy outcome

    In cardioembolic stroke patients after thrombectomy, Cerebrolysin reduced mRS scores at all visits versus historical controls.

    In plain wordsIn stroke patients after thrombectomy, Cerebrolysin reduced disability scores at all visits versus historical controls.

    Peptide
    Cerebrolysin
    Outcome
    DecreasemRS scores
    Study

    n = 150

    Comparator
    Historical controls receiving mechanical thrombectomy without Cerebrolysin
    Outcome group
    Neuroprotection · Nervous system and cognition
    Studied dose
    30 ml daily · 14 daysAs given in this study (human).

    Source sentences

    Summary
    This finding was consistent with lower NIHSS and mRS scores at all study visits, and a lower any hemorrhagic transformation rate (20% vs. 57.3%).
    3 context sentences
    Summary · context
    Data were prospectively collected from 75 patients with cardioembolic AIS and National Institutes of Health Stroke Scale (NIHSS) ≥10, who underwent successful MT ± recombinant tissue plasminogen activator (rt-PA).
    Summary · context
    Patients fulfilling inclusion criteria were consecutively enrolled and treated with Cerebrolysin at a daily dose of 30 ml for 14 days, with treatment initiated within 8 h following MT.
    Summary · context
    Patients were compared with a historical control group of 75 well-matched patients who underwent MT ± rt-PA but did not receive Cerebrolysin.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    14 Oct 2026, 05:02 UTC

    Study results updated

  2. Version 1

    14 Oct 2026, 01:46 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.